Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this year.

Novo Nordisk faces challenges but its pipeline remains strong. Find out why NVO stock could deliver high double-digit returns ...

Novo Nordisk (NVO) CEO Lars Jørgensen isn't too worried about the upcoming Medicare price negotiations over blockbuster GLP-1 drugs, even though the company still stands with the industry against ...

Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks Consensus Estimate for quarterly revenues in the to-be-reported quarter is ...

More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.

Novo Nordisk (NVO), a pharmaceutical company, isn’t too worried about the U.S. government’s plan to negotiate prices for its popular diabetes ...

Healthcare costs and spending have been rising in the US. The Centers for Medicare & Medicaid Services reported that ...

While the issue has fallen from the headlines after several moves to cap the cost, some patients with diabetes still often ...

U.S. President Donald Trump is set to meet with top pharmaceutical executives on Thursday, a White House official confirmed. The discussions will focus on Medicare drug price negotiations, pharmacy ...

Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

Eli Lilly (LLY) stock and Novo Nordisk (NVO) stock face investor scrutiny as RFK Jr. takes the leadership of HHS. Read more ...